Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor.
Ikeda
Y
Y
Department of Internal Medicine, Keio University, Tokyo, Japan. yikeda@mc.med.keio.ac.jp
D000818:Animals; D001792:Blood Platelets / Q000502:physiology; D002455:Cell Division / Q000187:drug effects; D000077407:Cilostazol; D002986:Clinical Trials as Topic; D000242:Cyclic AMP / Q000502:physiology; D005343:Fibrinolytic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007383:Intermittent Claudication / Q000188:drug therapy; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D013777:Tetrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000494:pharmacology* / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D000960:Hypolipidemic Agents; D010726:Phosphodiesterase Inhibitors; D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D014665:Vasodilator Agents; D000242:Cyclic AMP; D000077407:Cilostazol